3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
39
INDUSTRY
32
NIH
2
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
3
Gliosarcoma
2
Glioblastoma
2
Central Nervous System Neoplasms
2
Breast Neoplasms, Male
2
Waldenstrom Macroglobulinemia
1
Somatostatinoma
1
Sarcoma
1
Rhabdoid Tumor
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Osteosarcoma
1
Mesothelioma, Malignant
1
Meningioma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Kidney Neoplasms
1
Insulinoma
1
Immunoblastic Lymphadenopathy
1
Glucagonoma
1
Interventions
Gemcitabine
3
Carboplatin
3
cabozantinib
2
Magnetic Resonance Spectroscopy
2
Interferon-alpha
2
Granulocyte Colony-Stimulating Factor
2
Gene Expression Profiling
2
Filgrastim
2
Etoposide
2
Doxorubicin
2
Cyclophosphamide
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
siltuximab
1
pembrolizumab
1
peginterferon alfa-2b
1
pegfilgrastim
1
pazopanib
1
lenvatinib
1
fludarabine
1
aldesleukin
1
Vincristine
1
Thrombopoietin
1
Taxes
1
Surgical Procedures, Operative
1
Sunitinib
1
Standard of Care
1
Specimen Handling
1
Radiotherapy
1
Radiosurgery
1
Radiation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Carcinoma, Renal Cell
×
Everolimus
×
Clear all
NCT01120249
2025-09-16
S0931
SWOG Cancer Research Network
Phase 3
Completed
1,545 enrolled
15 charts